A Novel Treatment for Ewing’s Sarcoma: Chimeric Antigen Receptor-T Cell Therapy
Open Access
- 10 September 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
Abstract
Ewing’s sarcoma (EWS) is a malignant and aggressive tumor type that predominantly occurs in children and adolescents. Traditional treatments such as surgery, radiotherapy and chemotherapy, while successful in the early disease stages, are ineffective in patients with metastases and relapses who often have poor prognosis. Therefore, new treatments for EWS are needed to improve patient’s outcomes. Chimeric antigen receptor (CAR)-T cells therapy, a novel adoptive immunotherapy, has been developing over the past few decades, and is increasingly popular in researches and treatments of various cancers. CAR-T cell therapy has been approved by the Food and Drug Administration (FDA) for the treatment of leukemia and lymphoma. Recently, this therapeutic approach has been employed for solid tumors including EWS. In this review, we summarize the safety, specificity and clinical transformation of the treatment targets of EWS, and point out the directions for further research.This publication has 118 references indexed in Scilit:
- Antibody-dependent cell lysis by NK cells is preserved after sarcoma-induced inhibition of NK cell cytotoxicityCancer Immunology, Immunotherapy, 2013
- The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targetingBritish Journal of Cancer, 2012
- Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody ReceptorClinical Cancer Research, 2011
- Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2bJournal of Immunotherapy, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Adoptively transferred effector cells derived from naïve rather than central memory CD8 + T cells mediate superior antitumor immunityProceedings of the National Academy of Sciences of the United States of America, 2009
- Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen ExpressionMolecular Therapy, 2009
- The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in miceBritish Journal of Cancer, 2008
- VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing’s sarcoma vasculatureAngiogenesis, 2008
- Promiscuity and the single receptor: NKG2DNature Reviews Immunology, 2007